O	0	8	Decrease	Decrease	NN	B-NP
O	9	11	in	in	IN	B-PP
O	12	13	c	c	NN	B-NP
O	13	14	-	-	HYPH	I-NP
O	14	17	Myc	Myc	NN	I-NP
O	18	26	activity	activity	NN	I-NP
O	27	35	enhances	enhance	VBZ	B-VP
B-Cell	36	42	cancer	cancer	NN	B-NP
I-Cell	43	47	cell	cell	NN	I-NP
O	48	59	sensitivity	sensitivity	NN	I-NP
O	60	62	to	to	TO	B-PP
O	63	74	vinblastine	vinblastine	NN	B-NP
O	74	75	.	.	.	O

O	77	80	The	The	DT	B-NP
O	81	82	c	c	NN	I-NP
O	82	83	-	-	HYPH	I-NP
O	83	86	myc	myc	NN	I-NP
O	87	95	oncogene	oncogene	NN	I-NP
O	96	103	encodes	encode	VBZ	B-VP
O	104	107	for	for	IN	B-PP
O	108	109	a	a	DT	B-NP
O	110	125	transcriptional	transcriptional	JJ	I-NP
O	126	132	factor	factor	NN	I-NP
O	133	141	involved	involve	VBN	B-VP
O	142	144	in	in	IN	B-PP
O	145	149	many	many	JJ	B-NP
B-Cell	150	158	cellular	cellular	JJ	I-NP
O	159	168	processes	process	NNS	I-NP
O	169	173	such	such	JJ	B-PP
O	174	176	as	as	IN	I-PP
O	177	190	proliferation	proliferation	NN	B-NP
O	190	191	,	,	,	O
O	192	207	differentiation	differentiation	NN	B-NP
O	208	211	and	and	CC	O
O	212	221	apoptosis	apoptosis	NN	B-NP
O	221	222	.	.	.	O

O	223	232	According	Accord	VBG	B-PP
O	233	235	to	to	TO	B-PP
O	236	241	these	these	DT	B-NP
O	242	251	different	different	JJ	I-NP
O	252	261	functions	function	NNS	I-NP
O	261	262	,	,	,	O
O	263	266	the	the	DT	B-NP
O	267	271	role	role	NN	I-NP
O	272	274	of	of	IN	B-PP
O	275	276	c	c	NN	B-NP
O	276	277	-	-	HYPH	I-NP
O	277	280	Myc	Myc	NN	I-NP
O	281	288	protein	protein	NN	I-NP
O	289	291	in	in	IN	B-PP
B-Cell	292	300	cellular	cellular	JJ	B-NP
O	301	312	sensitivity	sensitivity	NN	I-NP
O	313	315	to	to	TO	B-PP
O	316	320	anti	anti	AFX	B-NP
O	320	321	-	-	HYPH	I-NP
B-Cancer	321	327	cancer	cancer	NN	I-NP
O	328	333	drugs	drug	NNS	I-NP
O	334	336	is	be	VBZ	B-VP
O	337	350	controversial	controversial	JJ	B-ADJP
O	350	351	.	.	.	O

O	352	354	We	We	PRP	B-NP
O	355	362	defined	define	VBD	B-VP
O	363	366	the	the	DT	B-NP
O	367	371	role	role	NN	I-NP
O	372	374	of	of	IN	B-PP
O	375	376	c	c	NN	B-NP
O	376	377	-	-	HYPH	O
O	377	380	Myc	Myc	NN	B-NP
O	381	383	in	in	IN	B-PP
B-Cell	384	390	cancer	cancer	NN	B-NP
I-Cell	391	395	cell	cell	NN	I-NP
O	396	407	sensitivity	sensitivity	NN	I-NP
O	408	410	to	to	TO	B-PP
O	411	422	vinblastine	vinblastine	NN	B-NP
O	423	424	(	(	(	O
O	424	427	VLB	VLB	NN	B-NP
O	427	428	)	)	)	O
O	429	434	using	use	VBG	B-VP
O	435	440	human	human	JJ	B-NP
B-Cell	441	446	colon	colon	NN	I-NP
I-Cell	447	453	cancer	cancer	NN	I-NP
I-Cell	454	459	cells	cell	NNS	I-NP
O	459	460	:	:	:	O
B-Cell	461	465	LoVo	LoVo	RB	B-NP
O	466	470	wild	wild	JJ	I-NP
O	470	471	-	-	HYPH	I-NP
O	471	475	type	type	NN	I-NP
O	476	478	or	or	CC	O
O	479	490	transfected	transfecte	VBN	B-VP
O	491	495	with	with	IN	B-PP
O	496	497	a	a	DT	B-NP
B-Cellular_component	498	505	plasmid	plasmid	NN	I-NP
O	506	516	containing	contain	VBG	B-VP
O	517	520	the	the	DT	B-NP
O	521	526	human	human	JJ	I-NP
O	527	528	c	c	NN	I-NP
O	528	529	-	-	HYPH	I-NP
O	529	532	myc	myc	NN	I-NP
O	533	537	gene	gene	NN	I-NP
O	538	540	in	in	IN	B-PP
O	541	550	antisense	antisense	JJ	B-NP
O	551	562	orientation	orientation	NN	I-NP
O	563	564	(	(	(	O
B-Cell	564	568	LoVo	LoVo	NN	B-NP
I-Cell	568	569	-	-	HYPH	B-NP
I-Cell	569	575	mycANS	mycANS	NN	I-NP
O	575	576	)	)	)	O
O	576	577	.	.	.	O

O	578	586	Analysis	Analysis	NN	B-NP
O	587	589	of	of	IN	B-PP
O	590	593	VLB	VLB	NN	B-NP
O	594	606	cytotoxicity	cytotoxicity	NN	I-NP
O	607	619	demonstrated	demonstrate	VBD	B-VP
O	620	621	a	a	DT	B-NP
O	622	623	3	3	CD	I-NP
O	623	624	-	-	HYPH	I-NP
O	624	628	fold	fold	JJ	I-NP
O	629	637	increase	increase	NN	I-NP
O	638	640	in	in	IN	B-PP
O	641	644	VLB	VLB	NN	B-NP
O	645	656	sensitivity	sensitivity	NN	I-NP
O	657	659	in	in	IN	B-PP
B-Cell	660	664	LoVo	LoVo	AFX	B-NP
I-Cell	664	665	-	-	HYPH	I-NP
I-Cell	665	671	mycANS	mycANS	NN	I-NP
I-Cell	672	677	cells	cell	NNS	I-NP
O	677	678	.	.	.	O

O	679	689	Comparison	Comparison	NN	B-NP
O	690	697	between	between	IN	B-PP
B-Cell	698	703	cells	cell	NNS	B-NP
O	704	712	revealed	reveal	VBD	B-VP
O	713	722	different	different	JJ	B-NP
O	723	732	apoptosis	apoptosis	NN	I-NP
O	733	741	kinetics	kinetic	NNS	I-NP
O	741	742	:	:	:	O
O	743	755	accumulation	accumulation	NN	B-NP
O	756	758	of	of	IN	B-PP
B-Cell	759	764	cells	cell	NNS	B-NP
O	765	767	in	in	IN	B-PP
O	768	771	sub	sub	AFX	B-NP
O	771	772	-	-	HYPH	I-NP
O	772	774	G1	G1	NN	I-NP
O	775	780	phase	phase	NN	I-NP
O	781	784	and	and	CC	O
O	785	789	poly	poly	NN	B-NP
O	789	790	(	(	(	O
O	790	793	ADP	ADP	NN	B-NP
O	793	794	-	-	HYPH	B-NP
O	794	800	ribose	ribose	NN	I-NP
O	800	801	)	)	)	O
O	802	812	polymerase	polymerase	NN	B-NP
O	813	821	cleavage	cleavage	NN	I-NP
O	822	830	occurred	occur	VBD	B-VP
O	831	838	earlier	earlier	RBR	B-ADVP
O	839	841	in	in	IN	B-PP
B-Cell	842	846	LoVo	LoVo	AFX	B-NP
I-Cell	846	847	-	-	HYPH	I-NP
I-Cell	847	853	mycANS	mycANS	NN	I-NP
O	853	854	.	.	.	O

O	855	859	Then	Then	RB	B-ADVP
O	859	860	,	,	,	O
O	861	863	we	we	PRP	B-NP
O	864	876	demonstrated	demonstrate	VBD	B-VP
O	877	878	a	a	DT	B-NP
B-Cellular_component	879	892	mitochondrial	mitochondrial	JJ	I-NP
I-Cellular_component	893	901	membrane	membrane	NN	I-NP
O	902	911	potential	potential	NN	I-NP
O	912	922	disruption	disruption	NN	I-NP
O	923	931	followed	follow	VBN	B-VP
O	932	934	by	by	IN	B-PP
O	935	945	cytochrome	cytochrome	NN	B-NP
O	946	947	c	c	NN	I-NP
O	948	955	release	release	NN	I-NP
O	956	960	that	that	WDT	B-NP
O	961	970	indicates	indicate	VBZ	B-VP
O	971	974	the	the	DT	B-NP
O	975	986	involvement	involvement	NN	I-NP
O	987	989	of	of	IN	B-PP
B-Cellular_component	990	1002	mitochondria	mitochondrion	NNS	B-NP
O	1003	1005	in	in	IN	B-PP
O	1006	1010	this	this	DT	B-NP
O	1011	1020	apoptotic	apoptotic	JJ	I-NP
O	1021	1030	signaling	signaling	NN	I-NP
O	1031	1038	pathway	pathway	NN	I-NP
O	1038	1039	.	.	.	O

O	1040	1044	This	This	DT	B-NP
O	1045	1052	earlier	early	JJR	I-NP
O	1053	1062	apoptosis	apoptosis	NN	I-NP
O	1063	1066	was	be	VBD	B-VP
O	1067	1078	accompanied	accompany	VBN	I-VP
O	1079	1081	by	by	IN	B-PP
O	1082	1083	a	a	DT	B-NP
O	1084	1087	Bcl	Bcl	NN	I-NP
O	1087	1088	-	-	HYPH	O
O	1088	1089	2	2	CD	B-NP
O	1090	1098	decrease	decrease	NN	I-NP
O	1099	1102	and	and	CC	O
O	1103	1104	a	a	DT	B-NP
O	1105	1108	p53	p53	NN	I-NP
O	1109	1117	increase	increase	NN	I-NP
O	1117	1118	.	.	.	O

O	1119	1121	In	In	IN	B-PP
O	1122	1132	conclusion	conclusion	NN	B-NP
O	1132	1133	,	,	,	O
O	1134	1137	the	the	DT	B-NP
O	1138	1146	decrease	decrease	NN	I-NP
O	1147	1149	in	in	IN	B-PP
O	1150	1151	c	c	NN	B-NP
O	1151	1152	-	-	HYPH	O
O	1152	1155	Myc	Myc	NN	B-NP
O	1156	1166	expression	expression	NN	I-NP
O	1167	1175	enhanced	enhance	VBD	B-VP
O	1176	1179	the	the	DT	B-NP
O	1180	1183	VLB	VLB	NN	I-NP
O	1184	1195	sensitivity	sensitivity	NN	I-NP
O	1195	1196	,	,	,	O
O	1197	1207	triggering	trigger	VBG	B-VP
O	1208	1215	earlier	early	JJR	B-NP
O	1216	1225	apoptosis	apoptosis	NN	I-NP
O	1226	1233	through	through	IN	B-PP
O	1234	1243	induction	induction	NN	B-NP
O	1244	1246	of	of	IN	B-PP
O	1247	1250	the	the	DT	B-NP
O	1251	1260	intrinsic	intrinsic	JJ	I-NP
O	1261	1268	pathway	pathway	NN	I-NP
O	1268	1269	.	.	.	O

O	1270	1274	Thus	Thus	RB	B-ADVP
O	1274	1275	,	,	,	O
O	1276	1277	c	c	NN	B-NP
O	1277	1278	-	-	HYPH	I-NP
O	1278	1281	myc	myc	NN	I-NP
O	1282	1291	induction	induction	NN	I-NP
O	1292	1294	is	be	VBZ	B-VP
O	1295	1296	a	a	DT	B-NP
O	1297	1307	resistance	resistance	NN	I-NP
O	1308	1314	factor	factor	NN	I-NP
O	1315	1318	and	and	CC	O
O	1319	1322	our	our	PRP$	B-NP
O	1323	1331	findings	finding	NNS	I-NP
O	1332	1339	suggest	suggest	VBP	B-VP
O	1340	1344	that	that	IN	B-SBAR
B-Cancer	1345	1351	tumors	tumor	NNS	B-NP
O	1352	1360	carrying	carry	VBG	B-VP
O	1361	1364	low	low	JJ	B-NP
O	1365	1371	levels	level	NNS	I-NP
O	1372	1374	of	of	IN	B-PP
O	1375	1376	c	c	NN	B-NP
O	1376	1377	-	-	HYPH	O
O	1377	1380	Myc	Myc	NN	B-NP
O	1381	1388	protein	protein	NN	I-NP
O	1389	1394	could	could	MD	B-VP
O	1395	1397	be	be	VB	I-VP
O	1398	1402	more	more	RBR	B-ADJP
O	1403	1413	responsive	responsive	JJ	I-ADJP
O	1414	1416	to	to	TO	B-PP
O	1417	1422	vinca	vinca	NN	B-NP
O	1423	1432	alkaloids	alkaloid	NNS	I-NP
O	1433	1442	treatment	treatment	NN	I-NP
O	1442	1443	.	.	.	O

O	1444	1452	Moreover	Moreover	RB	B-ADVP
O	1452	1453	,	,	,	O
O	1454	1457	the	the	DT	B-NP
O	1458	1472	downregulation	downregulation	NN	I-NP
O	1473	1475	of	of	IN	B-PP
O	1476	1477	c	c	NN	B-NP
O	1477	1478	-	-	HYPH	I-NP
O	1478	1481	myc	myc	NN	I-NP
O	1482	1490	oncogene	oncogene	NN	I-NP
O	1491	1493	by	by	IN	B-PP
O	1494	1496	an	an	DT	B-NP
O	1497	1506	antisense	antisense	JJ	I-NP
O	1507	1515	strategy	strategy	NN	I-NP
O	1516	1521	might	might	MD	B-VP
O	1522	1531	represent	represent	VB	I-VP
O	1532	1533	a	a	DT	B-NP
O	1534	1540	useful	useful	JJ	I-NP
O	1541	1545	goal	goal	NN	I-NP
O	1546	1549	for	for	IN	B-PP
O	1550	1559	improving	improve	VBG	B-VP
O	1560	1563	the	the	DT	B-NP
O	1564	1572	efficacy	efficacy	NN	I-NP
O	1573	1575	of	of	IN	B-PP
O	1576	1580	this	this	DT	B-NP
O	1581	1585	anti	anti	AFX	I-NP
O	1585	1586	-	-	HYPH	I-NP
B-Cancer	1586	1596	neoplastic	neoplastic	JJ	I-NP
O	1597	1601	drug	drug	NN	I-NP
O	1602	1608	family	family	NN	I-NP
O	1608	1609	.	.	.	O

